A head-to-head randomized controlled trial found similar remission rates for two leading biologic therapies for Crohn's disease: ustekinumab and adalimumab.
A head-to-head randomized controlled trial found similar remission rates for two leading biologic therapies for Crohn's disease: ustekinumab and adalimumab.
